Duchenne Muscular Dystrophy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | Santhera, Italfarmaco, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Sarepta Therapeutics, Wave Life Sciences Ltd

DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:
• The Duchenne Muscular Dystrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The National Organisation for Rare Diseases (NORD) states that DMD is the most prevalent form of muscular dystrophy that manifests in childhood and affects nearly exclusively males. The age of onset is often between three and five years, and the prevalence is estimated to be one in every 3,500 live male births
• In 2021, there were 30,933 DMD patients who were prevelant in the seven major markets, whereas there were 16,933 DMD patients who were prevelant in the US
• In the United States in 2021, the age categories of 5 to 9 years, 10 to 14 years, and 15 to 20 years saw the highest percentage of age-specific cases
• Scoliosis had the highest diagnosed prevalence of related comorbidities in DMD in the United States in 2021 (3,387).
• Key Duchenne Muscular Dystrophy Companies: Santhera, Italfarmaco, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Sarepta Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, PTC Therapeutics, RSPR Pharma AB, Daiichi Sankyo Co., Ltd., Wave Life Sciences Ltd., ReveraGen BioPharma, Inc., Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Pfizer, Capricor Therapeutics, and others
• Key Duchenne Muscular Dystrophy Therapies: Vamorolone, Givinostat, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, SRP-5051, WVE N531, PGN EDO51, UX810, Ataluren, CRD007, DS-5141b, WVE-N531, Vamorolone, Givinostat (ITF2357), ATL1102, SRP-9001, PF06939926, CAP-1002, and others
• The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females
• The Duchenne Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

Duchenne Muscular Dystrophy Overview
The most prevalent type of muscular dystrophy in children is Duchenne muscular dystrophy (DMD). One of nine kinds of muscular dystrophy, it is a hereditary illness characterised by gradual muscle weakness.

Get a Free sample for the Duchenne Muscular Dystrophy Market Report
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Duchenne Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Duchenne Muscular Dystrophy Epidemiology Segmentation:
The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Duchenne Muscular Dystrophy
• Prevalent Cases of Duchenne Muscular Dystrophy by severity
• Gender-specific Prevalence of Duchenne Muscular Dystrophy
• Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Duchenne Muscular Dystrophy Therapies and Key Companies
• Vamorolone: Santhera
• Givinostat: Italfarmaco
• Pamrevlumab: Fibrogen
• Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics
• EDG 5506: Edgewise Therapeutics
• SRP-5051: Sarepta Therapeutics
• WVE N531: Wave Life Sciences Ltd
• PGN EDO51: PepGen
• UX810: Ultragenyx Pharmaceutical
• Ataluren: PTC Therapeutics
• CRD007: RSPR Pharma AB
• DS-5141b: Daiichi Sankyo Co., Ltd.
• WVE-N531: Wave Life Sciences Ltd.
• Vamorolone: ReveraGen BioPharma, Inc.
• Givinostat (ITF2357): Italfarmaco
• ATL1102: Antisense Therapeutics
• SRP-9001: Sarepta Therapeutics
• PF06939926: Pfizer
• CAP-1002: Capricor Therapeutics

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy Treatment Market
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Duchenne Muscular Dystrophy Market Strengths
• The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development
• Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of Viltepso now.

Duchenne Muscular Dystrophy Market Opportunities
• Wider commercial opportunity for therapies such as Capricor's CAP-1002 and Antisense's ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

Scope of the Duchenne Muscular Dystrophy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Duchenne Muscular Dystrophy Companies: Santhera, Italfarmaco, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Sarepta Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, PTC Therapeutics, RSPR Pharma AB, Daiichi Sankyo Co., Ltd., Wave Life Sciences Ltd., ReveraGen BioPharma, Inc., Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Pfizer, Capricor Therapeutics, and others
• Key Duchenne Muscular Dystrophy Therapies: Vamorolone, Givinostat, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, SRP-5051, WVE N531, PGN EDO51, UX810, Ataluren, CRD007, DS-5141b, WVE-N531, Vamorolone, Givinostat (ITF2357), ATL1102, SRP-9001, PF06939926, CAP-1002, and others
• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
• Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Duchenne Muscular Dystrophy Unmet Needs, KOL's views, Analyst's views, Duchenne Muscular Dystrophy Market Access and Reimbursement

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Duchenne Muscular Dystrophy Market Report Introduction
2. Executive Summary for Duchenne Muscular Dystrophy
3. SWOT analysis of Duchenne Muscular Dystrophy
4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance
5. Duchenne Muscular Dystrophy Market Overview at a Glance
6. Duchenne Muscular Dystrophy Disease Background and Overview
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Duchenne Muscular Dystrophy
9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices
10. Duchenne Muscular Dystrophy Unmet Needs
11. Duchenne Muscular Dystrophy Emerging Therapies
12. Duchenne Muscular Dystrophy Market Outlook
13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2019-2032)
14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies
15. Duchenne Muscular Dystrophy Market Drivers
16. Duchenne Muscular Dystrophy Market Barriers
17. Duchenne Muscular Dystrophy Appendix
18. Duchenne Muscular Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Duchenne Muscular Dystrophy Pipeline
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Duchenne Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Duchenne Muscular Dystrophy market. A detailed picture of the Duchenne Muscular Dystrophy pipeline landscape is provided, which includes the disease overview and Duchenne Muscular Dystrophy treatment guidelines.
Duchenne Muscular Dystrophy Epidemiology
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Duchenne Muscular Dystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.